The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Efficacy of Lanreotide for the Treatment of Neuroendocrine Tumors

Martyn E. Caplin
Published Online: 7:52 PM, Sat October 17, 2015

 

Martyn E. Caplin, professor, lead clinician, Neuroendocrine Unit at the Royal Free Hospital, London, discusses the efficacy of lanreotide for the treatment of patients with neuroendocrine tumors, as shown in clinical trials such as the CLARINET study.



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.